Humanin

Mitochondrial-derived cytoprotective peptide

Key facts

Primary use

Cytoprotection / longevity

Evidence

Preclinical

Typical dose ranges

0.25-1 mg/day

Half-life

Short

Routes

subcutaneous

Long-form page in progress

The catalog summary above is what we have here. Mechanism, protocols, evidence detail, and safety notes are on the roadmap. Browse the full catalog or check the articles section for related context.